Основная статистика
| CIK | 1528115 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Annexon, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| August 14, 2025 |
Non-Employee Director Compensation Program. Exhibit 10.1 ANNEXON, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM This Annexon, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2020 Incentive Award Plan (the “Plan”) and shall be effective as of April 1, 2025. Capitalized terms not otherwise defined herein shall have the meaning ascribed in the Plan. Cash Compensation Annua |
|
| August 14, 2025 |
Exhibit 99.1 Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA Accelerated Completion of Enrollment for Global Phase 3 |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39402 ANNEXON, IN |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 25, 2025 |
Form of Common Warrant Amendment. Exhibit 4.1 ANNEXON, INC. AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT This AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT, dated as of June [•], 2025 (this “Amendment”), amends that certain COMMON STOCK PURCHASE WARRANT (the “Warrant”), dated as of July 11, 2022, by Annexon, Inc. (the “Company”) for the benefit of the holder thereof or its assigns (“Holder”). The Company and Holder are refe |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39402 ANNEXON, I |
|
| May 12, 2025 |
Exhibit 99.1 Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission Open-Label Tanruprubart FORWARD Study Designed to Broaden Patient and Healthcare Community Experience in North America and |
|
| May 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorporation |
|
| April 23, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the (Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted b |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the (Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)). ☐ De |
|
| March 3, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Annexon, Inc. (Exact name of Registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Title of Securities to be Registered Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Co |
|
| March 3, 2025 |
Exhibit 99.1 Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting Targeted for 1H 2025 Ahead of Planned Biologics License Application (BLA) Submission Established Groundbreaking Global Registrat |
|
| March 3, 2025 |
Power of Attorney (included on the signature page of this Form S-8) As filed with the U.S. Securities and Exchange Commission on March 3, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Annexon, Inc. (Exact name of registrant as specified in its charter) Delaware 27-5414423 (State or other jurisdiction of incorporation or organization) (I.R.S. Em |
|
| March 3, 2025 |
Insider Trading Compliance Policy Exhibit 19.1 ANNEXON, Inc. INSIDER TRADING compliance POLICY (Effective as of July 27, 2020, as amended on March 16, 2023) This Insider Trading Compliance Policy (this “Policy”) consists of seven sections: • Section I provides an overview; • Section II sets forth policies of Annexon, Inc. (the “Company”) prohibiting insider trading; • Section III explains insider trading; • Section IV consists of |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39402 ANNEXON, INC. ( |
|
| March 3, 2025 |
Non-Employee Director Compensation Program. Exhibit 10.10 ANNEXON, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM This Annexon, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2020 Incentive Award Plan (the “Plan”) and shall be effective as of April 1, 2024. Capitalized terms not otherwise defined herein shall have the meaning ascribed in the Plan. Cash Compensation Annu |
|
| March 3, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| January 13, 2025 |
Exhibit 99.1 Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year ANX005 First Potential Targeted Therapy for Guillain-Barré Syndrome Advancing Towards 1H 2025 BLA Submission ANX007 First Potential Neuroprotective Therapy for Geographic Atrophy Expected to Complete Enrollment of Phase 3 ARCHER II Trial in 2H 2025 ANX1502 First Oral C1s Inhibitor On Track for Clini |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 10, 2025 |
Exhibit 99.1 Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones Seasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operations BRISBANE, Calif., January 10, 2025 – Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with dev |
|
| December 19, 2024 |
As filed with the Securities and Exchange Commission on December 19, 2024. S-8 As filed with the Securities and Exchange Commission on December 19, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Annexon, Inc. (Exact name of Registrant as specified in its charter) Delaware 27-5414423 (State or other jurisdiction of incorporation or organization) (I.R.S. |
|
| December 19, 2024 |
EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Annexon, Inc. (Exact name of Registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Title of Securities to be Registered Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registrati |
|
| December 16, 2024 |
Exhibit 99.1 Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS) Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Pre |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 14, 2024 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G EX-99.A 2 d895401dex99a.htm EX-99.A Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments th |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39402 ANNEXO |
|
| November 14, 2024 |
ANNX / Annexon, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d897811dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Annexon, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03589W102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the |
|
| November 14, 2024 |
ANNX / Annexon, Inc. / Bain Capital Life Sciences Fund, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d895401dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 4) ANNEXON, INC. (Name of Issuer) Common Stock, $0.001 par value p |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorpor |
|
| November 14, 2024 |
ANNX / Annexon, Inc. / Logos Global Management LP Passive Investment SC 13G/A 1 annx13ga2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Annexon, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 03589W102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| November 14, 2024 |
SC 13G/A 1 sc13ga307422annx11142024.htm AMENDMENT NO. 3 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Annexon, Inc. (Name of Issuer) Common Stock, par value $0.001 per |
|
| November 14, 2024 |
Exhibit 99.1 Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones Topline Real-World Evidence (RWE) Comparability and Outcomes Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected by Year-End 2024; Biologics License Application (BLA) Submission Targeted for First Half 2025 Ongoing Enrollment in Phase 3 ARCHER II Trial for ANX007 in Geographic Atro |
|
| November 12, 2024 |
ANNX / Annexon, Inc. / Adage Capital Management, L.P. - ANNEXON, INC. Passive Investment SC 13G/A 1 p24-3087sc13ga.htm ANNEXON, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Annexon, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03589W102 (CUSIP Number) September 30, 2024** (Date of Event Which Requires Filing of This Statement) Check the appropr |
|
| October 22, 2024 |
Exhibit 99.1 Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting Enhanced protection of vision with ANX007 treatment in healthier eyes Greater preservation of EZ in the central fovea by ANX007 in patients with less advanced GA Pivotal Phase 3 ARCHER II Data Expected Second Half 2026 BRISBANE, |
|
| October 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2024 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Num |
|
| September 27, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Annexon, Inc. |
|
| September 27, 2024 |
As filed with the Securities and Exchange Commission on September 27, 2024. S-8 As filed with the Securities and Exchange Commission on September 27, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Annexon, Inc. (Exact name of Registrant as specified in its charter) Delaware 27-5414423 (State or other jurisdiction of incorporation or organization) (I.R. |
|
| August 13, 2024 |
CORRESP August 13, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky Re: Annexon, Inc. Registration Statement on Form S-3 File No. 333-281493 Acceleration Request Requested Date: August 15, 2024 Requested Time: 4:00 PM Eastern Daylight Time Ladies and Gentlemen: In accordance with Rule 461 under the |
|
| August 12, 2024 |
EX-FILING FEES 4 d878941dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Annexon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregat |
|
| August 12, 2024 |
Exhibit 99.1 Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones Single, Well-Tolerated Infusion of ANX005 Significantly Accelerated Recovery of GBS Patients vs. Placebo in Pivotal Phase 3 Trial; Potential to be First Targeted Therapy for GBS; Topline Real-World Evidence (RWE) Comparability Data Now Expected by Year-End 2024 Dosing Initiated in ARCHE |
|
| August 12, 2024 |
As filed with the Securities and Exchange Commission on August 12, 2024 S-3 1 d878941ds3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on August 12, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 27-5414423 (State or other jurisdiction of i |
|
| August 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39402 ANNEXON, IN |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 5, 2024 |
EX-99.1 Exhibit 99.1 Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy Patient Dosing Initiated in Phase 3 ARCHER II Trial of C1q Inhibitor ANX007; Topline Data Expected in Second Half 2026 Additional Data from Phase 2 ARCHER Trial Demonstrated Both Significant Vision Protection in Standard and Low Light Conditions, and Significant Structural Protection in Re |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 25, 2024 |
Exhibit 99.1 Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints Two and a Half Times More ANX005-Treated Patients Returned to a Normal / Pre-Disease State |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 7, 2024 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-278246 Prospectus supplement (To prospectus dated April 1, 2024) 13,001,120 shares of common stock Pre-funded warrants to purchase 7,000,000 shares of common stock We are offering 13,001,120 shares of our common stock, par value $0.001 per share, or, in lieu of common stock to certain investors that so choose, pre-funded |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 7, 2024 |
Annexon Announces Pricing of $125 Million Underwritten Public Offering EX-99.1 Exhibit 99.1 Annexon Announces Pricing of $125 Million Underwritten Public Offering BRISBANE, Calif., June 5, 2024 — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the pricing of its p |
|
| June 7, 2024 |
Exhibit 1.1 Annexon, Inc. 13,001,120 Shares of Common Stock, par value $0.001 per share Pre-Funded Warrants to Purchase 7,000,000 Shares of Common Stock Underwriting Agreement June 5, 2024 J.P. Morgan Securities LLC Jefferies LLC TD Securities (USA) LLC BofA Securities, Inc. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue |
|
| June 7, 2024 |
EX-4.1 Exhibit 4.1 ANNEXON, INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. [•] Original Issue Date: June [•], 2024 Annexon, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitted registered assigns (the “Ho |
|
| June 6, 2024 |
Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated June 5, 2024 Relating to Preliminary Prospectus Supplement Dated June 4, 2024 Registration Statement No. |
|
| June 4, 2024 |
EX-99.2 Exhibit 99.2 Topline Results from Phase 3 Study of ANX005 in Guillain-Barré Syndrome 1 Forward-Looking Statements This presentation contains “forwardlo ‐ oking” statements about Annexon, Inc. and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts, including statements regarding our clinical and preclinical programs, timin |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 4, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-278246 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying pros |
|
| June 4, 2024 |
EX-99.1 Exhibit 99.1 Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome Single Infusion of ANX005 30 mg/kg Met Primary Endpoint, Delivering a Highly Statistically Significant and Clinically Meaningful 2.4-fold Improvement in GBS-DS vs. Placebo at Week 8, p=0.0058 ANX005 Demonstrated Early and Sustained Im |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39402 ANNEXON, I |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorporation |
|
| May 13, 2024 |
Exhibit 99.1 Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024; Potential to be the First Targeted Treatment for GBS New Phase 2 Data Showing Neuroprotection of Vision and Vision-Associated |
|
| May 7, 2024 |
EX-99.1 Exhibit 99.1 Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting ANX007 demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings ANX007 protected key retinal structures important for vision: significant reduction of ph |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 25, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the (Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted b |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the (Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)). ☐ De |
|
| April 22, 2024 |
EX-99.A Exhibit A Exhibit A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned. BB Biotech AG Date: April 22, 2024 By: /s/ Martin Gubler Signatory Authority Name: Martin Gubler Title: Signatory Authority Date: April 22, 2024 By: /s/ Ivo Betschart Signatory Authority |
|
| April 22, 2024 |
ANNX / Annexon, Inc. / BB BIOTECH AG - SC 13G Passive Investment SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Annexon, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03589W102 (CUSIP Number) April 17, 2024 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 1 |
|
| April 5, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Reg. No. 333-278246 PROSPECTUS $100,000,000 Common Stock We have entered into a sales agreement (the Sales Agreement) with Cowen and Company, LLC (TD Cowen), relating to the sale of shares of our common stock offered by this prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock, par value |
|
| March 28, 2024 |
March 28, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jason Drory Re: Annexon, Inc. Registration Statement on Form S-3 File No. 333-278246 Acceleration Request Requested Date: April 1, 2024 Requested Time: 4:00 PM Eastern Daylight Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities A |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39402 ANNEXON, INC. ( |
|
| March 26, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Annexon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry For |
|
| March 26, 2024 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 ANNEXON, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF ANNEXON, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ANNEXON, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having |
|
| March 26, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Annexon, Inc. (Exact name of Registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Title of Securities to be Registered Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity |
|
| March 26, 2024 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.8 ANNEXON, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF ANNEXON, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ANNEXON, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] a |
|
| March 26, 2024 |
As filed with the Securities and Exchange Commission on March 26, 2024. S-8 As filed with the Securities and Exchange Commission on March 26, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Annexon, Inc. (Exact name of Registrant as specified in its charter) Delaware 27-5414423 (State or other jurisdiction of incorporation or organization) (I.R.S. Em |
|
| March 26, 2024 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.7 ANNEXON, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF ANNEXON, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ANNEXON, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] a |
|
| March 26, 2024 |
Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.4 ANNEXON, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Section 2.03 |
|
| March 26, 2024 |
Sales Agreement, dated as of March 26, 2024, by and between Annexon Inc. and Cowen and Company, LLC. Exhibit 1.2 ANNEXON, INC. COMMON STOCK SALES AGREEMENT March 26, 2024 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Annexon, Inc. (the “Company”) confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen” or “Agent”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement, o |
|
| March 26, 2024 |
Exhibit 99.1 Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024, a Global Sham-Controlled Trial Using Vision Preservation as Primary Outcome Measure Clinic |
|
| March 26, 2024 |
Policy for Recovery of Erroneously Awarded Compensation. Exhibit 97.1 ANNEXON, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION The Board of Directors (the “Board”) of Annexon, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of November 15, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorporati |
|
| March 26, 2024 |
As filed with the Securities and Exchange Commission on March 26, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on March 26, 2024 Registration No. |
|
| March 4, 2024 |
EX-99.1 Exhibit 99.1 Virtual R&D Day | March 1, 2024 Nasdaq: ANNX Guillain-Barré Syndrome: A Focus on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach Douglas Love, President & CEO Annexon Biosciences 2 Forward-Looking Statements This presentation contains “forward‐looking” statements about Annexon, Inc. and our industry that involve substantial risks and uncertainties. All statemen |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2024 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Number |
|
| February 14, 2024 |
ANNX / Annexon, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) ANNEXON, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03589W102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 14, 2024 |
ANNX / Annexon, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Annexon, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (the “Shares”) (Title of Class of Securities) 03589W102 (CUSIP Numb |
|
| February 14, 2024 |
ANNX / Annexon, Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Annexon, Inc. (Name of Issuer – as specified in its charter) Common Stock, par value $0.001 per share (Title of Class of Securities) 03589W102 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 14, 2024 |
ANNX / Annexon, Inc. / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246235d12sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Annexon, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03589W102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check th |
|
| February 14, 2024 |
ANNX / Annexon, Inc. / Fairmount Funds Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ANNEXON, INC. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 03589W102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Annexon, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03589W102 (CUSIP Number) December 3 |
|
| February 14, 2024 |
EX-99.1 2 tm245846d18ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 p |
|
| February 13, 2024 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G EX-99.A 2 d753375dex99a.htm EX-99.A Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments th |
|
| February 13, 2024 |
ANNX / Annexon, Inc. / Bain Capital Life Sciences Fund, L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240. |
|
| February 13, 2024 |
ANNX / Annexon, Inc. / Logos Global Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Annexon, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 03589W102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 12, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-0840exhibit99.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing a |
|
| February 12, 2024 |
ANNX / Annexon, Inc. / Point72 Asset Management, L.P. - ANNEXON, INC. Passive Investment SC 13G 1 p24-0840sc13g.htm ANNEXON, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Annexon, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03589W102 (CUSIP Number) February 2, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| February 7, 2024 |
ANNX / Annexon, Inc. / ADAGE CAPITAL PARTNERS GP, L.L.C. - ANNEXON, INC. Passive Investment SC 13G/A 1 p24-0434sc13ga.htm ANNEXON, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Annexon, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03589W102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriat |
|
| January 8, 2024 |
EX-99.1 Exhibit 99.1 Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024; Potential to be First Approved Treatment for GBS Patients in the U.S. ANX007 Global Pivotal Program in Geographic Atrophy |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2024 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| December 22, 2023 |
Exhibit 4.1 ANNEXON, INC. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. [•] Original Issue Date: December 26, 2023 Annexon, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitted registered assigns (the “Holder |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File |
|
| December 21, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 21, 2023 |
25,035,000 Shares of Common stock Pre-funded Warrants to Purchase 18,379,861 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258863 Prospectus supplement (To prospectus dated May 3, 2022) 25,035,000 Shares of Common stock Pre-funded Warrants to Purchase 18,379,861 Shares of Common Stock Pursuant to this prospectus supplement and the accompanying base prospectus, we are offering 25,035,000 shares of our common stock, par value $0.001 per share, |
|
| December 21, 2023 |
Exhibit 1.1 Annexon, Inc. 25,035,000 Shares of Common Stock, par value $0.001 per share Pre-Funded Warrants to Purchase 18,379,861 Shares of Common Stock Underwriting Agreement December 20, 2023 Jefferies LLC Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Jefferies LLC 520 Madison Avenue New York, NY 10179 c/o Cowen and Company, LLC 599 Lexing |
|
| December 21, 2023 |
Exhibit 4.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THE HOLDER MAY NOT OFFER, SELL, TRANSFER, ASSIGN, PLEDGE, HYPOTHECATE, OR OTHERWISE DISPOSE OF OR ENCUMBER SUCH SECURITIES EXCEPT (I) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR PROSPECTUS UNDER THE SECURITIES ACT AND THE RULES AND REGULATIONS PROMULGAT |
|
| December 21, 2023 |
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock Exhibit 99.1 Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock BRISBANE, Calif., December 20, 2023 –– Annexon, Inc. (NASDAQ: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the pricing of an u |
|
| December 20, 2023 |
EX-99.2 Exhibit 99.2 Annexon Reports Phase 1 Results for ANX1502, Its Oral Small Molecule Inhibitor of the Classical Complement Pathway Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well-Tolerated Across Cohorts with No Serious Adverse Events Tablet Formulation of ANX |
|
| December 20, 2023 |
EX-99.3 ANX007 Phase 3 GA Program December 2023 Exhibit 99.3 Overview of ANX007 Geographic Atrophy Program Unique MOA targeting classical complement inflammation where it starts Preclinical classical complement inhibition protected photoreceptor cell loss and function ARCHER 1st clinical demonstration of significant, dose & time-dependent vision preservation Vision preservation supported by multip |
|
| December 20, 2023 |
Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated December 20, 2023 Relating to Prospectus Dated May 3, 2022 Registration Statement No. |
|
| December 20, 2023 |
EX-99.4 ANX1502 First In Human SAD / MAD Data Overview December 2023 Exhibit 99.4 Overview of ANX1502 Program Potential first oral small molecule inhibitor of the classical pathway in development, targeting the active form of C1s Successfully completed single and multidose Phase I study in healthy volunteers with liquid suspension formulation Observed desired PK (well above minimum targeted drug l |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 20, 2023 |
EX-99.1 Exhibit 99.1 Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint Alignment with FDA on Best Corrected Visual Acuity ≥ 15-Letter Loss as Primary Outcome Measure - Representing the Highest Value Outcome to Patients and Physicians ARCHER II, a Global Sham-Controlled Trial Supporting a Potentially Faster |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorpor |
|
| November 13, 2023 |
Exhibit 99.1 Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results Company Prioritizes Greatest Near-term Value-Driving Programs: ANX005 for Guillain-Barré Syndrome (GBS), ANX007 for Geographic Atrophy (GA) and First-in-Kind Complement Small Molecule, ANX1502 ANX005 Phase 3 Pivotal Data in GBS On Track for First Half of 2024 ANX007 Awarded First-E |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39402 ANNEXO |
|
| October 24, 2023 |
ANNEXON RECEIVES PRIME DESIGNATION FROM THE EMA FOR ANX007 FOR THE TREATMENT OF GEOGRAPHIC ATROPHY Exhibit 99.1 ANNEXON RECEIVES PRIME DESIGNATION FROM THE EMA FOR ANX007 FOR THE TREATMENT OF GEOGRAPHIC ATROPHY • PRIME Designation Granted Based on Phase 2 ARCHER Trial Results, which Showed Meaningful Preservation of Visual Function in Patients with Geographic Atrophy • ANX007 is the First Therapeutic Candidate to Receive PRIME Designation by the EMA for the Indication of Geographic Atrophy • Co |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 11, 2023 |
Exhibit 99.1 ANNEXON ANNOUNCES CLINICAL AND REGULATORY PROGRESS FOR ANX005 PIVOTAL PROGRAM IN GUILLAIN-BARRÉ SYNDROME (GBS) October 10, 2023 at 6:30 AM EDT - ANX005 Granted Orphan Drug Designation by the European Medicines Agency for the Treatment of GBS - Target Enrollment Achieved in Phase 3 Pivotal Study of ANX005 in GBS Representing the Company’s Third Successfully Executed Clinical Study in G |
|
| August 8, 2023 |
ANNX / Annexon Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2*) ANNEXON, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03589W102 (CUSIP Number) July 31, 2023 (Date of Event Which Requires Filing of this Statement) |
|
| August 7, 2023 |
Non-Employee Director Compensation Program. Exhibit 10.1 ANNEXON, INC. NON- EMPLOYEE DIRECTOR COMPENSATION PROGRAM This Annexon, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2020 Incentive Award Plan (the “Plan”) and shall be effective as of March 16, 2023. Capitalized terms not otherwise defined herein shall have the meaning ascribed in the Plan. Cash Compensation Ann |
|
| August 7, 2023 |
Employment Agreement by and between the Exhibit 10.2 ANNEXON, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), is made and entered into on July 27, 2023 by and between Annexon, Inc., a Delaware corporation (the “Company”) and Jamie Dananberg, M.D. (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated a |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39402 ANNEXON, IN |
|
| August 7, 2023 |
Exhibit 99.1 Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results ARCHER Trial Results Presented at ASRS Further Demonstrate Preservation of Visual Function in Patients with Geographic Atrophy; Company to Engage Regulatory Agencies to Determine Optimal Path Forward Multiple Key Catalysts Expected in Second Half 2023, Including Completion of Enr |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorporati |
|
| July 31, 2023 |
Exhibit 99.1 Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer BRISBANE, Calif., July 27, 2023 - Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disord |
|
| July 31, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 31, 2023 |
Exhibit 99.2 Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy Additional analyses support consistent protection from vision loss Annexon to engage with regulatory agencies to determine optimal path forward for ANX007 Company to hold investor conference call on Monday, July 31, 2023, at 1:30 p.m. PT / 4:30 p.m. |
|
| June 22, 2023 |
ANNX / Annexon Inc / Logos Global Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Annexon, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 03589W102 (CUSIP Number) June 13, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 30, 2023 |
ANNX / Annexon Inc / Bain Capital Life Sciences Fund, L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240. |
|
| May 30, 2023 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G EX-99.A Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completen |
|
| May 25, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 25, 2023 |
EX-99.1 Exhibit 99.1 Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function ARCHER data support ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection against vision loss in both foveal and non-foveal patients through 12 months Red |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39402 ANNEXON, I |
|
| May 8, 2023 |
Exhibit 99.1 Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress Initial Clinical Data Expected from the Phase 2 ARCHER Trial of ANX007 in Geographic Atrophy in Mid-2023 Initial Clinical Data Anticipated from the Phase 1b Trial of ANX009 in Lupus Nephritis in 1H’23 Enrollment Expected to be Completed in Phase 3 Trial in Guillain-Barré Syndrome During 2H’23, |
|
| May 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorporation) |
|
| May 8, 2023 |
Non-Employee Director Compensation Program. Exhibit 10.1 ANNEXON, INC. NON- EMPLOYEE DIRECTOR COMPENSATION PROGRAM This Annexon, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2020 Incentive Award Plan (the “Plan”) and shall be effective as of March 16, 2023. Capitalized terms not otherwise defined herein shall have the meaning ascribed in the Plan. Cash Compensation Ann |
|
| April 25, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)). |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorporati |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39402 ANNEXON, INC. ( |
|
| March 6, 2023 |
Employment Agreement by and between the Registrant and Dean Richard Artis, Ph.D. Exhibit 10.12 ANNEXON, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), is made and entered into on January 6, 2023 by and between Annexon, Inc., a Delaware corporation (the “Company”) and Dean Richard Artis (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated a |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023. S-8 As filed with the Securities and Exchange Commission on March 6, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Annexon, Inc. (Exact name of Registrant as specified in its charter) Delaware 27-5414423 (State or other jurisdiction of incorporation or organization) (I.R.S. Employ |
|
| March 6, 2023 |
EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Annexon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0 |
|
| March 6, 2023 |
Exhibit 99.1 Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones Initial Clinical Data from Phase 2 Trial of ANX007 in Patients with Geographic Atrophy On-track for Mid-2023 Oral Small Molecule ANX1502, for Autoimmune Indications, Advances into Multi-Ascending Dose Trial Well-capitalized with Operating Runway into 2025, Including through Multipl |
|
| February 27, 2023 |
ANNX / Annexon Inc / CITADEL ADVISORS LLC - ANNEXON, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Annexon, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (the “Shares”) (Title of Class of Securities) 03589W102 (CUSIP Numbe |
|
| February 27, 2023 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Annexon, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned. This |
|
| February 17, 2023 |
ANNX / Annexon Inc / Satter Muneer A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Annexon, Inc. (Name of issuer) Common Stock, par value $0.001 (Title of class of securities) 03589W102 (CUSIP nu |
|
| February 14, 2023 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G EX-99.A Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completen |
|
| February 14, 2023 |
ANNX / Annexon Inc / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment SC 13G/A 1 annexoninc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Annexon, Inc. (Name of Issuer – as specified in its charter) Common Stock, par value $0.001 per share (Title of Class of Securities) 03589W102 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statemen |
|
| February 14, 2023 |
ANNX / Annexon Inc / Fairmount Funds Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm235981d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ANNEXON, INC. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 03589W102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Annexon, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03589W102 (CUSIP Number) December 3 |
|
| February 14, 2023 |
EX-99.1 2 tm236041d3ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 pa |
|
| February 14, 2023 |
ANNX / Annexon Inc / ALLIANCEBERNSTEIN L.P. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Annexon Inc (Name of Issuer) Common Stock (Title of Class of Securities) 03589W102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 14, 2023 |
ANNX / Annexon Inc / Bain Capital Life Sciences Fund, L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240. |
|
| February 14, 2023 |
ANNX / Annexon Inc / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm236041d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) ANNEXON, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 03589W102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 14, 2023 |
ANNX / Annexon Inc / Venrock Healthcare Capital Partners II, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236635d5sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Annexon, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03589W102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the |
|
| February 9, 2023 |
ANNX / Annexon Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - ANNEXON, INC. Passive Investment SC 13G/A 1 p23-0745sc13ga.htm ANNEXON, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Annexon, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03589W102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriat |
|
| February 3, 2023 |
ANNX / Annexon Inc / PICTET ASSET MANAGEMENT SA - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Annexon Inc (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03589W102 (CUSIP Number) 12/31/2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 1, 2023 |
ANNX / Annexon Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1*) ANNEXON, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03589W102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Stateme |
|
| January 9, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2023 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| January 9, 2023 |
Exhibit 99.1 GAME-CHANGING MEDICINES FOR COMPLEMENT- MEDIATED DISEASES JANUARY 2023 Nasdaq: ANNX 1 Forward-Looking Statements This presentation contains “forward‐looking” statements about Annexon, Inc. the outcomes of any future collaboration agreements; and our ability to and our industry that involve substantial risks and uncertainties. All adequately maintain intellectual property rights for ou |
|
| January 9, 2023 |
EX-99.2 3 d422908dex992.htm EX-99.2 Exhibit 99.2 Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with Operating Runway into 2025 Company to Pre |
|
| January 6, 2023 |
Exhibit 99.1 Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio BRISBANE, Calif., Jan. 6, 2023 ? Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| November 16, 2022 |
42,137,548 Shares Common Stock Offered by the Selling Securityholders Table of Contents As Filed Pursuant to Rule 424(b)(3) Registration No. 333-268181 PROSPECTUS 42,137,548 Shares Common Stock Offered by the Selling Securityholders This prospectus relates to the proposed resale or other disposition of up to an aggregate of 42,137,548 shares of common stock, par value $0.001 per share (?common stock?), by the selling securityholders identified in this prospectus, of |
|
| November 14, 2022 |
Annexon, Inc. 1400 Sierra Point Parkway, Bldg C, Suite 200 Brisbane, California 94005 Annexon, Inc. 1400 Sierra Point Parkway, Bldg C, Suite 200 Brisbane, California 94005 November 14, 2022 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Annexon, Inc. Registration Statement on Form S-3 Filed November 4, 2022 Registration No. 333-268181 To whom it may concern: Pursuant to |
|
| November 4, 2022 |
EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Table Registration Statement on Form S-3 (Form Type) Annexon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price( |
|
| November 4, 2022 |
As filed with the Securities and Exchange Commission on November 4, 2022 S-3 Table of Contents As filed with the Securities and Exchange Commission on November 4, 2022 Registration No. |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39402 ANNEXO |
|
| November 3, 2022 |
Exhibit 99.1 Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023 Company to provide portfolio updates across autoimmune, neurodegeneration and ophthalmology therapeutic franchises in early January Presentations at upcoming scientific conferences highlight company?s novel approach to treating complement-mediated disea |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| August 8, 2022 |
2022 Employment Inducement Award Plan Exhibit 10.2(a) annexon, Inc. 2022 EMPLOYMENT INDUCEMENT AWARD PLAN ARTICLE I. Purpose The Plan?s purpose is to enhance the Company?s ability to attract, retain and motivate employees who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. ARTICLE II. Definitions As used in the Plan, the following words and phrases have th |
|
| August 8, 2022 |
Exhibit 99.1 Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results Advancing Robust Pipeline of Five Clinical-Stage Product Candidates Following ANX105 and ANX1502 Phase 1 Trial Initiations Multiple Clinical Readouts Anticipated throughout 2022 and 2023 Operating Runway into the Second Half of 2025 Following |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorporati |
|
| August 8, 2022 |
Exhibit 10.2(b) ANNEXON, INC. 2022 EMPLOYMENT INDUCEMENT AWARD PLAN STOCK OPTION GRANT NOTICE Annexon, Inc., a Delaware corporation, (the ?Company?), pursuant to its 2022 Employment Inducement Award Plan, as may be amended from time to time (the ?Plan?), hereby grants to the holder listed below (?Participant?), an option to purchase the number of shares of the Company?s Common Stock (the ?Shares?) |
|
| August 8, 2022 |
As filed with the Securities and Exchange Commission on August 8, 2022. As filed with the Securities and Exchange Commission on August 8, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Annexon, Inc. (Exact name of Registrant as specified in its charter) Delaware 27-5414423 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer |
|
| August 8, 2022 |
Exhibit 10.2(c) ANNEXON, INC. 2022 EMPLOYMENT INDUCEMENT AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Annexon, Inc., a Delaware corporation, (the ?Company?), pursuant to its 2022 Employment Inducement Award Plan, as amended from time to time (the ?Plan?), hereby grants to the holder listed below (the ?Participant?), an award of restricted stock units (?Restricted Stock Units? or ?RSUs?). Ea |
|
| August 8, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Annexon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par v |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39402 ANNEXON, IN |
|
| July 18, 2022 |
ANNX / Annexon Inc / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) ANNEXON, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 03589W102 (CUSIP Number) July 7, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| July 18, 2022 |
ANNX / Annexon Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - ANNEXON, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Annexon, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03589W102 (CUSIP Number) July 7, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| July 18, 2022 |
LEeasdf Exhibit C LOCK-UP AGREEMENT July 6, 2022 JEFFERIES LLC COWEN AND COMPANY, LLC As Placement Agents Jefferies LLC 520 Madison Avenue New York, NY 10022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Re: Annexon, Inc. |
|
| July 18, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.001 par value per share, of Annexon, Inc., which m |
|
| July 18, 2022 |
ANNX / Annexon Inc / Satter Muneer A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 Annexon, Inc. (Name of issuer) Common Stock, par value $0.001 (Title of class of securities) 03589W102 (CUSIP number) Muneer A. Sa |
|
| July 8, 2022 |
Exhibit 4.2 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?). THE HOLDER MAY NOT OFFER, SELL, TRANSFER, ASSIGN, PLEDGE, HYPOTHECATE, OR OTHERWISE DISPOSE OF OR ENCUMBER SUCH SECURITIES EXCEPT (I) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR PROSPECTUS UNDER THE SECURITIES ACT AND THE RULES AND REGULATIONS PROMULGAT |
|
| July 8, 2022 |
Exhibit 4.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?). THE HOLDER MAY NOT OFFER, SELL, TRANSFER, ASSIGN, PLEDGE, HYPOTHECATE, OR OTHERWISE DISPOSE OF OR ENCUMBER SUCH SECURITIES EXCEPT (I) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR PROSPECTUS UNDER THE SECURITIES ACT AND THE RULES AND REGULATIONS PROMULGAT |
|
| July 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2022 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorporation |
|
| July 8, 2022 |
Securities Purchase Agreement, dated July 7, Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 7, 2022, among Annexon, Inc., a corporation incorporated under the laws of the state of Delaware (the ?Company?), and the purchasers identified on the signature pages hereto (including their successors and assigns, the ?Purchasers?). WHEREAS, subject to the terms and conditions set |
|
| July 8, 2022 |
Annexon Announces $130 Million Private Placement Financing Exhibit 99.1 Annexon Announces $130 Million Private Placement Financing BRISBANE, Calif., July 8, 2022 ?? Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has entered into a securities purchase agreeme |
|
| July 8, 2022 |
Investor Presentation July 2022 Exhibit 99.2 Forward-Looking Statements This presentation contains ?forward?looking? statements about Annexon, Inc. and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts, including statements regarding our clinical and preclinical programs, timing and commencement of future nonclinical studies and |
|
| June 23, 2022 |
ANNX / Annexon Inc / Venrock Healthcare Capital Partners II, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Annexon, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03589W102 (CUSIP Number) June 13, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant |
|
| June 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 7, 2022 |
Exhibit 99.1 Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington?s Disease ANX005 Demonstrated Full C1q Target Inhibition and Was Generally Well-Tolerated Disease Progression Stabilized in Overall Patient Population Through the Nine-month Study Rapid Improvement in Clinical Outcome Measures |
|
| May 26, 2022 |
ANNX / Annexon Inc / BIOTECHNOLOGY VALUE FUND L P - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Annexon, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03589W102 (CUSIP Number) May 16, 202 |
|
| May 26, 2022 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated May 26, 2022 with respect to the Common Stock, $0.001 par value per share of Annexon, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisio |
|
| May 9, 2022 |
Non-Employee Director Compensation Program. Exhibit 10.1 ANNEXON, INC. NON- EMPLOYEE DIRECTOR COMPENSATION PROGRAM This Annexon, Inc. (the ?Company?) Non-Employee Director Compensation Program (this ?Program?) has been adopted under the Company?s 2020 Incentive Award Plan (the ?Plan?) and shall be effective as of the Company?s 2022 annual stockholder meeting (the ?2022 Annual Meeting?). Capitalized terms not otherwise defined herein shall h |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39402 ANNEXON, I |
|
| May 9, 2022 |
Exhibit 99.1 Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results Pioneering Upstream Complement-Targeted Platform with Broad Portfolio of Five Differentiated Product Candidates Anticipating Eight Clinical Catalysts Across Robust Pipeline throughout 2022 and 2023 BRISBANE, Calif., May 9, 2022 - Annexon, Inc. (Nasdaq: ANN |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorporation) |
|
| May 3, 2022 |
As filed with the Securities and Exchange Commission on May 3, 2022 As filed with the Securities and Exchange Commission on May 3, 2022 Registration No. |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.???) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. ? Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| April 27, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.???) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement. ?? Confidential, for Use of the Commission Only (as |
|
| April 21, 2022 |
ANNX / Annexon Inc / Fairmount Funds Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ANNEXON, INC. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 03589W102 (CUSIP Number) Erin O’Connor Fairmount Funds Management LLC 2001 Market Street, Suite 2501 Philadelphia, PA 19103 (267) 229-2730 (Name, Address and Tele |
|
| April 7, 2022 |
Exhibit 99.1 Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy Topline efficacy and safety data expected in first half of 2023 BRISBANE, Calif., Apr. 7, 2022 - Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complemen |
|
| April 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2022 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 2, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Annexon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par v |
|
| March 2, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. |
|
| March 2, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022. As filed with the Securities and Exchange Commission on March 1, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Annexon, Inc. (Exact name of Registrant as specified in its charter) Delaware 27-5414423 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer I |
|
| March 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39402 ANNEXON, INC. ( |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. |
|
| March 1, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Annexon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry F |
|
| March 1, 2022 |
Exhibit 99.1 Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results Multiple Value-Creating Catalysts Across Complement-Targeted Portfolio Anticipated Through 2023 Encouraging Interim Data Reported from Phase 2 Study of ANX005 for Huntington?s Disease; Full Data Expected in the Second Quarter of 2022 $243 Million in Cash and Investments at |
|
| March 1, 2022 |
Exhibit 4.3 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Annexon, Inc. has common stock, $0.001 par value per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), and listed on The Nasdaq Global Select Market under the trading symbol ?ANNX.? DESCRIPTION OF CAPITAL STOCK The fol |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 14, 2022 |
ANNX / Annexon Inc / CITADEL ADVISORS LLC - ANNEXON, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 2)* Annexon Inc (Name of Issuer) Common Stock, $0.001 par value per share (the ?Shares?) (Title of Class of Securities) 03589W102 (CUSIP Number |
|
| February 14, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.001 par value per share, of Annexon, Inc., which m |
|
| February 14, 2022 |
ANNX / Annexon Inc / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) ANNEXON, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 03589W102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 14, 2022 |
ANNX / Annexon Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. *) ANNEXON, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03589W102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statemen |
|
| February 14, 2022 |
ANNX / Annexon Inc / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Annexon, Inc. (Name of Issuer ? as specified in its charter) Common Stock, $0.001 par value (Title of Class of Securities) 03589W102 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 14, 2022 |
ANNX / Annexon Inc / ALLIANCEBERNSTEIN L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Annexon Inc (Name of Issuer) Common Stock (Title of Class of Securities) 03589W102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 11, 2022 |
EXHIBIT 99.3 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the shares of Common Stock, par value $0.001 per share, of Annexon, Inc., a Delaware corporation, and further agree that this Join |
|
| February 11, 2022 |
ANNX / Annexon Inc / Novartis Bioventures Ltd - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2022 |
ANNX / Annexon Inc / PICTET ASSET MANAGEMENT SA - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Annexon Inc (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03589W102 (CUSIP Number) 12/31 /2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 9, 2022 |
ANNX / Annexon Inc / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No. 1 ANNEXON INC COMMON STOCK Cusip #03589W102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #03589W102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 231,623 Item 6: 0 Item 7: 1,340,027 Item 8: 0 Item 9: 1,340,02 |
|
| February 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2022 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 20, 2022 |
Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors Exhibit 99.1 Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors BRISBANE, Calif., January 20, 2022 - Annexon, Inc. (?Annexon?) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced the appointment |
|
| January 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2022 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 10, 2022 |
EX-99.1 2 d223215dex991.htm EX-99.1 Exhibit 99.1 40th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 11, 2022 Forward-looking Statements This presentation and accompanying oral presentation contain “forward‐looking” statements about Annexon, Inc. and our industr y that involve substantial risks and uncertainties. All statements other than statements of historical facts, including statements rega |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 4, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2022 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 4, 2022 |
Exhibit 99.1 Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington?s Disease Following Six-Month Treatment ANX005 Has Been Generally Well-Tolerated and Has Shown Full Target Engagement of C1q in the CSF Improvements in Clinical Outcome Measures Observed in Greater than 50% of All Evaluable Patients and 75% of Evaluable Patient |
|
| November 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Annexon, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03589W102 (CUSIP Number) November 4, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursu |
|
| November 9, 2021 |
Exhibit 99.1 Annexon Biosciences Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results $271 Million Cash and Investments at End of Third Quarter 2021 Supports Operating Runway into 2024, Including Several Key Clinical Milestones across the Portfolio SOUTH SAN FRANCISCO, Calif., Nov. 9, 2021 - Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical comp |
|
| November 9, 2021 |
Employment Agreement by and between the Registrant and Larry Mattheakis, Ph.D Exhibit 10.2 ANNEXON, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is made and entered into by and between Annexon, Inc., a Delaware corporation (the ?Company?) and Larry Mattheakis (?Executive? and, together with the Company, the ?Parties?) effective as of September 27, 2021 (the ?Effective Date?). This Agreement supersedes in its entirety that certain offer letter betwee |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39402 ANNEXO |
|
| October 4, 2021 |
Exhibit 99.1 ANNEXON BIOSCIENCES FURTHER STRENGTHENS ITS EXECUTIVE LEADERSHIP TEAM WITH APPOINTMENT OF TED YEDNOCK, PH.D., TO CHIEF INNOVATION OFFICER AND APPOINTMENT OF LARRY MATTHEAKIS, PH.D., AS CHIEF SCIENTIFIC OFFICER ? Dr. Ted Yednock?s appointment enhances Annexon?s commitment to scientific innovation and pursuit of future programs ? ? Dr. Larry Mattheakis brings decades of drug discovery a |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 ANNEXON, INC. (Exact name of registrant as specified in its charter) Delaware 001-39402 27-5414423 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 27, 2021 |
ANNX / Annexon Inc / Blackstone Holdings II L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Annexon, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03589W102 (CUSIP Number) Robert Liptak Clarus Ventures, LLC 101 Main Street, Suite 1210 Cambridge, MA 02142 (617) 949-2200 (Name, Address and |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39402 ANNEXON, IN |
|
| August 16, 2021 |
Sales Agreement, dated August 16, 2021, by and between Annexon, Inc. and Cowen and Company, LLC Exhibit 10.1 Annexon, Inc. COMMON STOCK SALES AGREEMENT August 16, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Annexon, Inc. (the ?Company?) confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement, on the ter |
|
| August 16, 2021 |
Exhibit 4.4 ANNEXON, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establishment of Te |
